The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Castle Biosciences (CSTL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
FRIENDSWOOD, Texas, May 15, 2024--Castle executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference May 29 at 2pm ET.